

# Project 1

## Clinical

### Aim 1: Mek (AZD6244) Clinical Trial

**Pediatric**

**Adult**

#### Data to be Collected

- PK
- Cytokine
- cHSPCs (Angio)
- Sequencing
- Kinome
- Pathology/Histology
- Tumor Data (i.e. #/size/volume)

**Upload into Synapse**

## Pre-Clinical

### Aim 2: Mek & c-Kit inhibition in pN Mouse Model

#### Drug Groups

- AZD6244
- Gleevec
- AZD6244 + Gleevec
- AZD6244 Holiday Schedule
- Controls
- XL184
- XL184 + AZD6244

#### Data to be Collected

- PK
- Kinome
- Tumor Data (#/size/volume)
- Pathology/Histology

### Aim 3: Role of c-Kit during pN Development

#### Drug Groups

- None

#### Data to be Collected

- Tumor Data (#/size/volume)
- Pathology/Histology
- pNF Tumor Progression

#### Other Linked Studies Outside SPORE Endpoints for Validation Enrichment

- Cabozantinib (XL184) Clinical Trial (Pediatrics)
- Cabozantinib (XL184) Clinical Trial (Adults)
- Plexiform neurofibroma (pNF) and Atypical Neurofibromas (ANF) for Kinome [Matt Steensma, VAI]
- Phase II Imatinib (Gleevec) Clinical Trial
- pNF Patient Data w/KRAS Mutation [CHOP]

**Upload into Synapse**